Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor
This study will test whether half matched donors with favorable KIR genes will reduce the risk of cancer recurring after transplant.
Hematologic Malignancy
DRUG: melphalan|DRUG: fludarabine|DRUG: thiotepa|DRUG: Cyclophosphamide|DRUG: Mesna|DRUG: Mycophenolate Mofetil|DRUG: Filgrastim|DRUG: Tacrolimus
Proportion of Patients Undergoing an Allo HCT Transplant Who Have a KIR Favorable Donor., 1 year
This study will test whether half matched donors with favorable KIR genes will reduce the risk of cancer recurring after transplant.